Fig. 6
From: Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy
Combining PCSK9 inhibitors with OVA-II vaccines triggers better anti-tumor effects in the melanoma mouse model. (A) Schematic of PCSK9i combined with OVA-II vaccine treatment schedule in B16F10-OVA challenged syngeneic melanoma model. C57BL/6-line mice are s.c. injected with 105 B16F10-OVA cells (n = 6 per group) and treated i.p. with PCSK9i (5 mg/kg), DMSO, treated s.c. with OVA-II vaccine (10ug/mouse), PCSK9i(5 mg/kg) combined with OVA-II vaccine (10ug/mouse) every other day for 18 days. Mice were sacrificed via cervical dislocation at the treatment endpoint, and (B) tumors were harvested for analysis. (C-D) Tumor weights and volumes of B16F10-OVA-bearing C57BL/6-line mice (n = 6 per group). (E) Weights of B16F10-OVA-bearing mice in two groups. Data with error bars are shown as mean ± SEM